149 related articles for article (PubMed ID: 31230347)
1. Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer.
Wang P; Zhang H; Yang J; Li Z; Wang Y; Leng X; Ganapathy S; Isakson P; Chen C; Zhu T
J Cell Physiol; 2020 Jan; 235(1):408-420. PubMed ID: 31230347
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor Sp1 is upregulated by PKCι to drive the expression of YAP1 during pancreatic carcinogenesis.
Yang J; Wang J; Zhang H; Li C; Chen C; Zhu T
Carcinogenesis; 2021 Apr; 42(3):344-356. PubMed ID: 33146712
[TBL] [Abstract][Full Text] [Related]
3. PKCι and YAP1 are crucial in promoting pancreatic tumorigenesis.
Wang P; Wei D; Zhang H; Chen J; Zhang D; Ganapathy S; Isakson P; Chen C; Zhu T
Oncotarget; 2018 Aug; 9(67):32736-32750. PubMed ID: 30214681
[TBL] [Abstract][Full Text] [Related]
4. A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion.
Butler AM; Scotti Buzhardt ML; Erdogan E; Li S; Inman KS; Fields AP; Murray NR
Oncotarget; 2015 Jun; 6(17):15297-310. PubMed ID: 25915428
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase Ciota is required for pancreatic cancer cell transformed growth and tumorigenesis.
Scotti ML; Bamlet WR; Smyrk TC; Fields AP; Murray NR
Cancer Res; 2010 Mar; 70(5):2064-74. PubMed ID: 20179210
[TBL] [Abstract][Full Text] [Related]
6. PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.
Wang Y; Justilien V; Brennan KI; Jamieson L; Murray NR; Fields AP
Oncogene; 2017 Jan; 36(4):534-545. PubMed ID: 27321186
[TBL] [Abstract][Full Text] [Related]
7. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
[TBL] [Abstract][Full Text] [Related]
8. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
9. GNAS
Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
[TBL] [Abstract][Full Text] [Related]
10. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic activity of Ect2 is regulated through protein kinase C iota-mediated phosphorylation.
Justilien V; Jameison L; Der CJ; Rossman KL; Fields AP
J Biol Chem; 2011 Mar; 286(10):8149-8157. PubMed ID: 21189248
[TBL] [Abstract][Full Text] [Related]
12. Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.
Yin N; Liu Y; Khoor A; Wang X; Thompson EA; Leitges M; Justilien V; Weems C; Murray NR; Fields AP
Cancer Cell; 2019 Aug; 36(2):156-167.e7. PubMed ID: 31378680
[TBL] [Abstract][Full Text] [Related]
13. YAP1-Mediated Suppression of USP31 Enhances NFκB Activity to Promote Sarcomagenesis.
Ye S; Lawlor MA; Rivera-Reyes A; Egolf S; Chor S; Pak K; Ciotti GE; Lee AC; Marino GE; Shah J; Niedzwicki D; Weber K; Park PMC; Alam MZ; Grazioli A; Haldar M; Xu M; Perry JA; Qi J; Eisinger-Mathason TSK
Cancer Res; 2018 May; 78(10):2705-2720. PubMed ID: 29490948
[TBL] [Abstract][Full Text] [Related]
14. Ect2 links the PKCiota-Par6alpha complex to Rac1 activation and cellular transformation.
Justilien V; Fields AP
Oncogene; 2009 Oct; 28(41):3597-607. PubMed ID: 19617897
[TBL] [Abstract][Full Text] [Related]
15. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase C iota regulates pancreatic acinar-to-ductal metaplasia.
Scotti ML; Smith KE; Butler AM; Calcagno SR; Crawford HC; Leitges M; Fields AP; Murray NR
PLoS One; 2012; 7(2):e30509. PubMed ID: 22359542
[TBL] [Abstract][Full Text] [Related]
17. Androgen attenuates the inactivating phospho-Ser-127 modification of yes-associated protein 1 (YAP1) and promotes YAP1 nuclear abundance and activity.
Cinar B; Al-Mathkour MM; Khan SA; Moreno CS
J Biol Chem; 2020 Jun; 295(25):8550-8559. PubMed ID: 32376689
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of atypical protein kinase C (PKCι and PKCζ) and its relationship with yes-associated protein in lung adenocarcinoma.
Kim KH; Chung C; Kim JM; Lee D; Cho SY; Lee TH; Cho HJ; Yeo MK
BMC Cancer; 2019 Aug; 19(1):804. PubMed ID: 31412817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
